Thomas Kahan

Dr. Thomas Kahan

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2001 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
ALA. C. Laska
A. C. Laska
AHA. Hellblom
A. Hellblom
VMV. Murray
V. Murray
Thomas KahanThomas Kahan
Thomas Kahan
MAM. Von Arbin
M. Von Arbin
Laska AC, Hellblom A, Murray V, Kahan T, von Arbin M (Danderyd Hospital, Danderyd, Sweden). Aphasia in acute stroke and relation to outcome. J Intern Med 2001; 249: 413–422. Objectives. The natural course of aphasia in unselected, consecutive stroke patients is not well established. We investigated morbidity, mortality and recovery for different types of aphasia in consecutive unselected aphasic patients with acute stroke. Setting and subjects. In 119 aphasic patients, the type and degree of aphasia were assessed acutely and at 3, 6 and 18 months after stroke onset, using Reinvang’s ‘Grunntest for afasi’ and Amsterdam‐Nijmegen‐Everyday‐Language‐Test. Results. About one‐third of patients with acute stroke had presented with aphasia. Mortality among the aphasic patients during the 18‐month follow‐up was twice that in non‐aphasics (36 vs. 16%). Presence of atrial fibrillation was associated with poorer prognosis. At 18 months, 24% of the 119 aphasic patients had recovered completely, 43% still had significant aphasia, and 21% had died. The proportion with global aphasia decreased from almost 25% acutely to a few per cent after 18 months, that with Wernicke’s aphasia from 25% to less than 10%, whereas conduction aphasia increased from 13 to 23% during follow‐up. Among those with initial mild aphasia, 70% recovered completely. Great improvement was observed in patients with initial low degree of speech function. Younger patients recovered to a greater extent than older patients. Conclusion. The high long‐term mortality among aphasics may be seen as an indirect sign of advanced cardiovascular disease. A combination of different and adjusted aphasia tests provided the possibility to assess almost all acute aphasic patients. Irrespective of type and degree of aphasia, great improvements were seen in almost all aphasic patients. Even patients with severe speech impairment have a considerable potential for recovery, particularly in the first 3 months after stroke.

9 January 2009 in European Heart Journal
Verified
Journal Article
Open access
PDF file
Jean-Claude TardifJean-Claude Tardif
Jean-Claude Tardif
PPPiotr Ponikowski
Piotr Ponikowski
Thomas KahanThomas Kahan
Thomas Kahan
FIfor the ASSOCIATE study Investigators
for the ASSOCIATE study Investigators
To evaluate the anti-anginal and anti-ischaemic efficacy of the selective If current inhibitor ivabradine in patients with chronic stable angina pectoris receiving beta-blocker therapy. In this double-blinded trial, 889 patients with stable angina receiving atenolol 50 mg/day were randomized to receive ivabradine 5 mg b.i.d. for 2 months, increased to 7.5 mg b.i.d. for a further 2 months, or placebo. Patients underwent treadmill exercise tests at the trough of drug activity using the standard Bruce protocol for randomization and at 2 and 4 months. Total exercise duration at 4 months increased by 24.3 ± 65.3 s in the ivabradine group, compared with 7.7 ± 63.8 s with placebo (P < 0.001). Ivabradine was superior to placebo for all exercise test criteria at 4 months (P < 0.001 for all) and 2 months (P-values between <0.001 and 0.018). Ivabradine in combination with atenolol was well tolerated. Only 1.1% of patients withdrew owing to sinus bradycardia in the ivabradine group. The combination of ivabradine 7.5 mg b.i.d. and atenolol at the commonly used dosage in clinical practice in patients with chronic stable angina pectoris produced additional efficacy with no untoward effect on safety or tolerability.

1 September 2013 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
RZRamin Zarrinkoub
Ramin Zarrinkoub
BWBjörn Wettermark
Björn Wettermark
PWPer Wändell
Per Wändell
MMMärit Mejhert
Märit Mejhert
RSRobert Szulkin
Robert Szulkin
Thomas KahanThomas Kahan
Thomas Kahan
Aims: The epidemiology of congestive heart failure (CHF) is likely to have changed due to changes in demography, risk factors, diagnostic procedures, and medical care. Prevailing information is in part old, incomplete, and to some extent contradictory. We determined the current prevalence, incidence, mortality, and 5-year survival rate of CHF, and possible temporal changes in Sweden. Methods and results: This was a cross-sectional study on individual patient data from an administrative health data register in the Stockholm region, Sweden, comprising 2.1 million inhabitants. This contained all recorded diagnoses on all consultations in primary and secondary care (defined as specialist outpatient care), and on all hospitalizations. Prevalence, incidence, and mortality were estimated for the entire Swedish population, adjusted for demographic composition in 2010. The study population consisted of 88 038 patients (51% women). The prevalence was 2.2% (both women and men), the incidence was 3.8/1000 person-years (both women and men), and mortality was 3.2/1000 person-years in women and 3.0/1000 person-years in men (P < 0.001); the 5-year survival rate was 48%. Mortality (age adjusted; hazard ratio and 95% confidence intervals) was higher in men, 1.29, 1.24—1.34; P < 0.001. Prevalence remained essentially unchanged from 2006 to 2010, while incidence decreased by 24% (P < 0.001) and mortality by 19% (both women and men; P < 0.001). Conclusions: The estimated prevalence of CHF in Sweden is 2.2%, incidence 3.8/1000 person-years, and mortality 3.1/1000 person-years. There has been a decrease in incidence and mortality from 2006 to 2010 in both women and men, with no major change in prevalence over time.

22 September 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
EGEva Gerdts
Eva Gerdts
ISIsabella Sudano
Isabella Sudano
SBSofie Brouwers
Sofie Brouwers
Claudio  BorghiClaudio Borghi
Claudio Borghi
RBRosa Maria Bruno
Rosa Maria Bruno
GSGiovanni de Simone
Giovanni de Simone
There is strong evidence that sex chromosomes and sex hormones influence blood pressure (BP) regulation, distribution of cardiovascular (CV) risk factors and co-morbidities differentially in females and males with essential arterial hypertension. The risk for CV disease increases at a lower BP level in females than in males, suggesting that sex-specific thresholds for diagnosis of hypertension may be reasonable. However, due to paucity of data, in particularly from specifically designed clinical trials, it is not yet known whether hypertension should be differently managed in females and males, including treatment goals and choice and dosages of antihypertensive drugs. Accordingly, this consensus document was conceived to provide a comprehensive overview of current knowledge on sex differences in essential hypertension including BP development over the life course, development of hypertension, pathophysiologic mechanisms regulating BP, interaction of BP with CV risk factors and co-morbidities, hypertension-mediated organ damage in the heart and the arteries, impact on incident CV disease, and differences in the effect of antihypertensive treatment. The consensus document also highlights areas where focused research is needed to advance sex-specific prevention and management of hypertension.

18 January 2005 in Heart
Verified
Journal Article
Open access
PDF file
Thomas KahanThomas Kahan
Thomas Kahan
LBLennart Bergfeldt
Lennart Bergfeldt
The presence of LV hypertrophy is a strong independent risk factor for future cardiac events and all cause mortality.1 The risk for sudden cardiac death is increased in subjects with LV hypertrophy, independent of the aetiology, and this event occurs also in individuals with no or only mild prior symptoms related to cardiovascular disease. Intense animal and human research has identified some common features and provided a framework within which some crucial components can be explained. Thus, whether the focus is haemodynamic or electrophysiologic, there seems to be consensus as to the initiation of a fetal-like gene programme in myocardial hypertrophy.2, 3 The insights into its consequences can be applied in the clinical management of individual patients.

26 September 2013 in Journal of Human Hypertension
Verified
Journal Article
Open access
PDF file
APAlexandre Persu
Alexandre Persu
YJY Jin
Y Jin
MAM Azizi
M Azizi
MBM Baelen
M Baelen
SVS Völz
S Völz
JSJan Albert Staessen
Jan Albert Staessen
We did a subject-level meta-analysis of the changes (Δ) in blood pressure (BP) observed 3 and 6 months after renal denervation (RDN) at 10 European centers. Recruited patients (n=109; 46.8% women; mean age 58.2 years) had essential hypertension confirmed by ambulatory BP. From baseline to 6 months, treatment score declined slightly from 4.7 to 4.4 drugs per day. Systolic/diastolic BP fell by 17.6/7.1 mm Hg for office BP, and by 5.9/3.5, 6.2/3.4, and 4.4/2.5 mm Hg for 24-h, daytime and nighttime BP (P0.03 for all). In 47 patients with 3- and 6-month ambulatory measurements, systolic BP did not change between these two time points (P0.08). Normalization was a systolic BP of <140 mm Hg on office measurement or <130 mm Hg on 24-h monitoring and improvement was a fall of 10 mm Hg, irrespective of measurement technique. For office BP, at 6 months, normalization, improvement or no decrease occurred in 22.9, 59.6 and 22.9% of patients, respectively; for 24-h BP, these proportions were 14.7, 31.2 and 34.9%, respectively. Higher baseline BP predicted greater BP fall at follow-up; higher baseline serum creatinine was associated with lower probability of improvement of 24-h BP (odds ratio for 20-μmol l−1 increase, 0.60; P=0.05) and higher probability of experiencing no BP decrease (OR, 1.66; P=0.01). In conclusion, BP responses to RDN include regression-to-the-mean and remain to be consolidated in randomized trials based on ambulatory BP monitoring. For now, RDN should remain the last resort in patients in whom all other ways to control BP failed, and it must be cautiously used in patients with renal impairment.